SCHEMBL7485100

SCHEMBL7485100

NC(Cc1c[nH]c2cccc(Br)c12)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.62
KDM4E B2RXH2 3/20 0.62
MAPT P10636 3/20 0.62
MEN1 O00255 3/20 0.62
LMNA P02545 2/20 0.62
TSHR P16473 2/20 0.62
BLM P54132 2/20 0.62
PMP22 Q01453 2/20 0.62
MPO P05164 1/20 0.62
HIF1A Q16665 1/20 0.62
ALDH1A1 P00352 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
CYP3A4 P08684 1/20 0.51
HTR1A P08908 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
ALOX15 P16050 1/20 0.51
NFKB1 P19838 1/20 0.51
HTR2A P28223 1/20 0.51
HTR2C P28335 1/20 0.51
SLC6A4 P31645 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7485105 1.00 KMT2A (0.62) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL18029238 1.00 KMT2A (0.62) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL458570 0.84 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL30356567 0.84 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL27917618 0.84 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL7480435 0.84 KMT2A (0.63) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL30084863 0.84 KMT2A (0.68) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL28409192 0.84 SMN1; SMN2 (0.61) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL1114867 0.84 KMT2A (0.68) KMT2AKDM4EMAPTMEN1LMNA
SCHEMBL18029267 0.84 KMT2A (0.68) KMT2AKDM4EMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-08-06 US claimed
EP-3678683-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF Fog Pharmaceuticals, Inc. (US) 2020-07-15 EP claimed
CN-111372942-A β -catenin function modulating agents and methods thereof 弗格制药有限公司 2020-07-03 CN claimed
WO-2019051327-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2019-03-14 WO claimed
EP-1219603-A2 Tryptophan analogs in proteins, peptides and peptidic structures Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2002-07-03 EP claimed
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS UNIV DANMARKS TEKNISKE (DK) 2025-11-20 US disclosed
EP-4526426-A2 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS Danmarks Tekniske Universitet (DK) 2025-03-26 EP disclosed
EP-3596089-B1 ANTIBACTERIAL COMPOUNDS UNIV NOTTINGHAM (GB) 2023-12-06 EP disclosed
US-11834482-B2 Agents modulating beta-catenin functions and methods thereof FOG PHARMACEUTICALS, INC. (US) 2023-12-05 US disclosed
WO-2023222879-A2 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS DANMARKS TEKNISKE UNIVERSITET (DK) 2023-11-23 WO disclosed
US-20230357744-A1 ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2023-11-09 US disclosed
US-20220290196-A1 GENETICALLY ENGINEERED MICROBES AND BIOSYNTHETIC METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-09-15 US disclosed
US-10752927-B2 Method for the synthesis of tryptophan analogs in aqueous solvents at reduced temperatures CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2020-08-25 US disclosed
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2020-08-06 US disclosed
EP-3678683-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF Fog Pharmaceuticals, Inc. (US) 2020-07-15 EP disclosed
CN-111372942-A β -catenin function modulating agents and methods thereof 弗格制药有限公司 2020-07-03 CN disclosed
US-20200199118-A1 ANTIBACTERIAL COMPOUNDS THE UNIVERSITY OF NOTTINGHAM (GB) 2020-06-25 US disclosed
US-20190271016-A1 METHOD FOR THE SYNTHESIS OF TRYPTOPHAN ANALOGS IN AQUEOUS SOLVENTS AT REDUCED TEMPERATURES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-05 US disclosed
WO-2019051327-A2 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF FOG PHARMACEUTICALS, INC. (US) 2019-03-14 WO disclosed
EP-1219603-A2 Tryptophan analogs in proteins, peptides and peptidic structures Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2002-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200199118-A1 ANTIBACTERIAL COMPOUNDS CFTR, CLPP, MRPL21 KMT2A 4669/4885KDM4E 4470/4885MAPT 3616/4885
US-20200247858-A1 AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF CTNNB1, CTNNBL1, CTNNA1 KMT2A 3036/4885KDM4E 1902/4885MAPT 3674/4885
US-20250354108-A1 METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS INMT, KARS1, MIA3 KMT2A 445/4885KDM4E 2243/4885MAPT 3008/4885
US-11834482-B2 Agents modulating beta-catenin functions and methods thereof CTNNB1, CTNNBL1, CTNNA1 KMT2A 3036/4885KDM4E 1902/4885MAPT 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.